OncoMatch/Clinical Trials/NCT06756334
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Is NCT06756334 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including [18F]AlF-PSMA-N5 and [18F]F-DCFPyL for prostate cancer.
Treatment: [18F]AlF-PSMA-N5 · [18F]F-DCFPyL — To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[18F\]F-DCFPyL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 imaging avidity
simultaneous [18F]AlF-PSMA-N5 and [18F]F-DCFPyL examinations within two weeks
Required: FOLH1 imaging avidity
simultaneous [18F]AlF-PSMA-N5 and [18F]F-DCFPyL examinations within two weeks
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06756334 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require FOLH1?
Yes, FOLH1 imaging avidity is a required biomarker for enrollment.
Does this trial require FOLH1?
Yes, FOLH1 imaging avidity is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages